SG11201508061UA - Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency - Google Patents
Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiencyInfo
- Publication number
- SG11201508061UA SG11201508061UA SG11201508061UA SG11201508061UA SG11201508061UA SG 11201508061U A SG11201508061U A SG 11201508061UA SG 11201508061U A SG11201508061U A SG 11201508061UA SG 11201508061U A SG11201508061U A SG 11201508061UA SG 11201508061U A SG11201508061U A SG 11201508061UA
- Authority
- SG
- Singapore
- Prior art keywords
- opa1
- haploinsufficiency
- treatment
- transcription factors
- diseases caused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13162189 | 2013-04-03 | ||
PCT/EP2014/056590 WO2014161881A1 (en) | 2013-04-03 | 2014-04-02 | Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201508061UA true SG11201508061UA (en) | 2015-10-29 |
Family
ID=48044671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508061UA SG11201508061UA (en) | 2013-04-03 | 2014-04-02 | Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency |
Country Status (16)
Country | Link |
---|---|
US (1) | US20160039893A1 (en) |
EP (1) | EP2981550A1 (en) |
JP (1) | JP2016515596A (en) |
KR (1) | KR20160003691A (en) |
CN (1) | CN105358568A (en) |
AR (1) | AR095983A1 (en) |
AU (1) | AU2014247131A1 (en) |
BR (1) | BR112015025285A2 (en) |
CA (1) | CA2908419A1 (en) |
EA (1) | EA201591626A1 (en) |
MA (1) | MA38543A1 (en) |
PH (1) | PH12015502294A1 (en) |
SG (1) | SG11201508061UA (en) |
TN (1) | TN2015000436A1 (en) |
TW (1) | TW201514200A (en) |
WO (1) | WO2014161881A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020506948A (en) * | 2017-02-07 | 2020-03-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Gene therapy for haploinsufficiency |
CA3091799A1 (en) * | 2018-02-27 | 2019-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered immune cells as diagnostic probes of disease |
CN110857440B (en) | 2018-08-23 | 2021-02-19 | 武汉纽福斯生物科技有限公司 | Recombinant human II type mitochondrial dynamic protein sample GTP enzyme gene sequence and application thereof |
WO2023129940A1 (en) | 2021-12-30 | 2023-07-06 | Regel Therapeutics, Inc. | Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof |
-
2014
- 2014-04-01 AR ARP140101461A patent/AR095983A1/en unknown
- 2014-04-01 TW TW103112110A patent/TW201514200A/en unknown
- 2014-04-02 EP EP14718351.1A patent/EP2981550A1/en not_active Withdrawn
- 2014-04-02 CA CA2908419A patent/CA2908419A1/en not_active Abandoned
- 2014-04-02 SG SG11201508061UA patent/SG11201508061UA/en unknown
- 2014-04-02 CN CN201480031898.7A patent/CN105358568A/en active Pending
- 2014-04-02 EA EA201591626A patent/EA201591626A1/en unknown
- 2014-04-02 WO PCT/EP2014/056590 patent/WO2014161881A1/en active Application Filing
- 2014-04-02 AU AU2014247131A patent/AU2014247131A1/en not_active Abandoned
- 2014-04-02 US US14/781,710 patent/US20160039893A1/en not_active Abandoned
- 2014-04-02 BR BR112015025285A patent/BR112015025285A2/en not_active Application Discontinuation
- 2014-04-02 KR KR1020157031596A patent/KR20160003691A/en not_active Application Discontinuation
- 2014-04-02 JP JP2016505805A patent/JP2016515596A/en active Pending
-
2015
- 2015-09-28 TN TN2015000436A patent/TN2015000436A1/en unknown
- 2015-10-02 PH PH12015502294A patent/PH12015502294A1/en unknown
- 2015-10-21 MA MA38543A patent/MA38543A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016515596A (en) | 2016-05-30 |
EP2981550A1 (en) | 2016-02-10 |
CN105358568A (en) | 2016-02-24 |
PH12015502294A1 (en) | 2016-02-15 |
AR095983A1 (en) | 2015-11-25 |
US20160039893A1 (en) | 2016-02-11 |
TW201514200A (en) | 2015-04-16 |
EA201591626A1 (en) | 2016-05-31 |
AU2014247131A1 (en) | 2015-10-22 |
MA38543A1 (en) | 2017-02-28 |
WO2014161881A1 (en) | 2014-10-09 |
TN2015000436A1 (en) | 2017-01-03 |
BR112015025285A2 (en) | 2017-10-10 |
CA2908419A1 (en) | 2014-10-09 |
KR20160003691A (en) | 2016-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2785706I2 (en) | SUBSTITUTED 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK-RECEPTOR-RELATED DISEASES | |
IL266648B (en) | Method for treatment of parkinson's disease | |
IL243976B (en) | Kdm1a inhibitors for the treatment of disease | |
EP3076948A4 (en) | Intracameral implant for treatment of an ocular condition | |
HK1220324A1 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
EP2981252A4 (en) | Methods of treating diseases characterized by excessive wnt signalling | |
IL239851B (en) | Methods and compositions for treatment of demyelinating diseases | |
EP2994460A4 (en) | Compounds for treatment of angiogenesis-mediated diseases | |
IL244042A0 (en) | Method for the treatment of fibrotic disease | |
EP2893903A4 (en) | Implantable device for moulding the curvature of the cornea | |
HK1219653A1 (en) | Methods for the treatment of mitochondrial disease | |
EP2967062A4 (en) | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation | |
HK1225385A1 (en) | Heteroaryl derivatives for the treatment of respiratory diseases | |
HK1225384A1 (en) | Benzhydryl derivatives for the treatment of respiratory diseases | |
HK1221190A1 (en) | The local treatment of inflammatory ophthalmic diseases | |
EP3021119A4 (en) | Method for diagnosis of diseases using morphological characteristics of luterial | |
SG11201508061UA (en) | Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency | |
IL243637B (en) | Ppar-sparing compounds for the treatment of metabolic diseases | |
IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
EP3030261A4 (en) | Methods of treatment of hpv related diseases | |
IL241482B (en) | Method for treatment of parkinson's disease | |
GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
AU2013901161A0 (en) | Methods of treating diseases characterized by excessive wnt signalling |